Activator of adiponectin receptor
US-2016214967-A1 · Jul 28, 2016 · US
Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes
US12098131B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12098131-B2 |
| Application number | US-202318299266-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 12, 2023 |
| Priority date | Dec 14, 2020 |
| Publication date | Sep 24, 2024 |
| Grant date | Sep 24, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are adiponectin receptor agonists and methods of using the same for the treatment of inflammation or bone loss in a subject.
First claim
Opening claim text (preview).
We claim: 1. A method for treating diabetes in a subject, the method comprising administering a compound or a pharmaceutically acceptable salt thereof to the subject, wherein the compound has a formula of wherein R 1 is —C(═O)R 4 and R 4 is a chloro-substituted phenyl; R 2 is a C 1 -C 4 alkoxyl, hydrogen, or 3,4-dichloro; R 3 is hydrogen or a C 1 -C 4 alkyl; and R 2 and R 3 are not both hydrogen; or wherein R 1 is —C(═O)R 4 and R 4 is an unsubstituted phenyl; R 2 is a C 1 -C 4 alkoxyl or hydrogen, or 3,4-dichloro; R 3 is hydrogen or a C 1 -C 4 alkyl; and R 2 and R 3 are not both hydrogen; or wherein R 1 is —C(═O)R 4 and R 4 is methyl; R 2 is a C 1 -C 4 alkoxyl or hydrogen; R 3 is hydrogen or a C 1 -C 4 alkyl; and R 2 and R 3 are not both hydrogen; or wherein R 1 is an unsubstituted phenyl; and R 2 is a C 1 -C 4 alkoxyl and R 3 is hydrogen or a C 1 -C 4 alkyl or R 2 is hydrogen and R 3 is hydrogen. 2. The method of claim 1 , wherein the subject has type 2 diabetes. 3. The method of claim 1 , wherein the subject has diabetes-associated bone loss. 4. The method of claim 1 , wherein the subject has periodontitis. 5. The method of claim 1 , wherein the subject has type 2 diabetes associated periodontitis. 6. The method of claim 1 , wherein the method comprises administering an effective amount of the compound to the subject to increase autophagy in osteoclasts. 7. The method of claim 1 , wherein the method comprises administering an effective amount of the compound to the subject to decrease fasting blood sugar. 8. The method of claim 1 , wherein the method comprises administering an effective amount of the compound to the subject to inhibit or reduce expression of a proinflammatory cytokine. 9. The method of claim 1 , wherein the method comprises administering an effective amount of the compound to the subject to increase expression of an anti-inflammatory cytokine. 10. The method of claim 1 , wherein the compound is an adiponectin receptor agonist. 11. The method of claim 1 , wherein R 1 is —C(═O)R 4 and R 4 is chloro-substituted phenyl. 12. The method of claim 11 , wherein R 4 is a 4-chloro substituted phenyl. 13. The method of claim 1 , wherein R 1 is —C(═O)R 4 and R 4 is unsubstituted phenyl. 14. The method of claim 13 , wherein R 1 is unsubstituted phenyl. 15. The method of claim 1 , wherein the compound is 16. The method of claim 1 , wherein the compound is 17. The method of claim 1 , wherein the compound is 18. A method for treating diabetes-associated bone loss in a subject, the method comprising administering a compound or a pharmaceutically acceptable salt thereof to the subject, wherein the compound has a formula of wherein R 1 is —C(═O)R 4 and R 4 is a chloro-substituted phenyl; R 2 is a C 1 -C 4 alkoxyl, hydrogen, or 3,4-dichloro; R 3 is hydrogen or a C 1 -C 4 alkyl; and R 2 and R 3 are not both hydrogen; or wherein R 1 is —C(═O)R 4 and R 4 is an unsubstituted phenyl; R 2 is a C 1 -C 4 alkoxyl or hydrogen, or 3,4-dichloro; R 3 is hydrogen or a C 1 -C 4 alkyl; and R 2 and R 3 are not both hydrogen; or wherein R 1 is —C(═O)R 4 and R 4 is methyl; R 2 is a C 1 -C 4 alkoxyl or hydrogen; R 3 is hydrogen or a C 1 -C 4 alkyl; and R 2 and R 3 are not both hydrogen; or wherein R 1 is an unsubstituted phenyl; and R 2 is a C 1 -C 4 alkoxyl and R 3 is hydrogen or a C 1 -C 4 alkyl or R 2 is hydrogen and R 3 is hydrogen. 19. The method of claim 18 , wherein the compound is 20. The method of claim 18 , wherein the compound is
Assignees
Inventors
Classifications
for bone diseases, e.g. rachitism, Paget's disease · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
- C07D211/58Primary
attached in position 4 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12098131B2 cover?
- Disclosed herein are adiponectin receptor agonists and methods of using the same for the treatment of inflammation or bone loss in a subject.
- Who is the assignee on this patent?
- Tufts College
- What technology area does this patent fall under?
- Primary CPC classification C07D211/58. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).